The primary patent protecting Invega (paliperidone palmitate) is set to expire in 2027 [1]. However, the landscape of drug patent expiration is complex and can be influenced by several factors.
What happens when Invega’s patent expires?
Upon the expiration of Invega's primary patent, the market may open to generic versions of the drug [1]. This typically leads to increased competition and potentially lower prices for the medication. However, other patents and exclusivities can affect the timeline for generic entry.
Are there other patents on Invega?
Drug manufacturers often secure multiple patents covering various aspects of a drug, including different formulations, methods of use, and manufacturing processes [1]. These additional patents can extend market exclusivity beyond the expiration of the initial patent. DrugPatentWatch.com tracks these patent details [1].
When can generic Invega be launched?
The precise date for generic Invega launch depends on the expiration of all relevant patents and any regulatory exclusivities granted by authorities like the U.S. Food and Drug Administration (FDA) [1]. Litigation involving patent challenges can also impact the availability of generics.
How do patent challenges affect Invega’s market?
Patent litigation is common in the pharmaceutical industry. Companies seeking to launch generic drugs often challenge existing patents, arguing they are invalid or that their product does not infringe them [1]. Successful challenges can lead to earlier generic market entry.
What is paliperidone palmitate and how is it used?
Paliperidone palmitate is the active ingredient in Invega, available as an injectable long-acting antipsychotic medication. It is used to treat schizophrenia and schizoaffective disorder [2].
Who makes Invega?
Invega is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [2].
How does Invega compare to other schizophrenia treatments?
Invega is one of several long-acting injectable antipsychotics available for managing schizophrenia and schizoaffective disorder. Treatment decisions are individualized based on patient needs, efficacy, and tolerability of different medications [2].
---
Sources
[1] DrugPatentWatch.com
[2] Janssen Pharmaceuticals